Greenwich LifeSciences Expands Clinical Trial into Portugal
Greenwich LifeSciences Expands Its Clinical Horizons
Greenwich LifeSciences, Inc. (NASDAQ: GLSI), based in Stafford, Texas, is making strides in the fight against breast cancer. The company, which specializes in biopharmaceuticals, has formally announced the expansion of its ongoing Phase III clinical trial, FLAMINGO-01, to include Portugal. This move enhances the trial's reach, further facilitating the evaluation of GLSI-100, an innovative immunotherapy aimed at preventing recurrences of breast cancer.
Approval for Portugal in FLAMINGO-01 Trials
Regulatory authorities in Europe have approved Greenwich LifeSciences’ application, allowing the inclusion of Portugal as part of the FLAMINGO-01 clinical trial. This addition is a significant step, as it complements the already existing sites in countries like Spain, France, Germany, Italy, Poland, Romania, Ireland, and the United States.
Breast Cancer Statistics in Portugal
The significance of this trial expansion lies in alarming statistics. According to the European Cancer Information System, over 9,000 new cases of breast cancer were reported in Portugal in a recent year, underscoring its status as the most common cancer among women, comprising roughly 30% of all cancer diagnoses. Tragically, it also stands as the leading cause of cancer-related deaths in women in Portugal, with over 2,200 deaths attributed to the disease in that same year.
Meet the National Principal Investigator
Dr. Luís António Marques da Costa, MD, PhD, will lead the FLAMINGO-01 trial in Portugal as the national principal investigator. He holds a notable position as an Associate Professor of Medicine, Oncology & Oncobiology at FML-UL in Lisbon, and heads the Clinical Translational Oncology Research Unit at the Institute of Molecular Medicine. Dr. Costa has contributed significantly to the field with his extensive involvement in various clinical trials including those targeting breast cancer and other solid tumors.
Collaborative Efforts for Better Outcomes
Snehal Patel, the CEO of Greenwich LifeSciences, expressed enthusiasm about working alongside Dr. Costa and his team. Recently, Patel visited Lisbon to initiate local activities and meet with investigators as they formulate strategies for the trial in Portugal. The company is actively pursuing additional clinical sites in central and northern regions of Portugal to broaden its reach.
Understanding the FLAMINGO-01 Clinical Trial and GLSI-100
FLAMINGO-01, identified by NCT05232916, is meticulously designed to assess the safety and efficacy of the investigational drug GLSI-100 (GP2 + GM-CSF) in patients diagnosed with HER2 positive breast cancer who have residual disease following surgery. The study involves randomizing about 500 patients for placebo or treatment groups, including a third arm for different HLA types, making it one of the promising trials aimed at reducing the chances of cancer recurrence.
Participants and Statistical Significance
In this ambitious Phase III trial, researchers are looking to achieve a statistically significant reduction in the chances of invasive breast cancer recurrence, with planned interim analyses to ensure the reliability of results. Envisioned to encompass up to 150 sites globally, the trial exemplifies a robust collaborative effort amongst leading universities and clinical entities.
About Breast Cancer, HER2, and Greenwich LifeSciences
Breast cancer remains a critical health issue, affecting one in eight women in the United States alone, leading to around 300,000 new cases annually. With a significant number of breast cancer survivors also in the population, the focus remains on effective treatment regimens, particularly for HER2 positive variants, which represent a substantial portion of breast cancer types. Greenwich LifeSciences is committed to developing an immunotherapy strategy that may significantly impact patient care and outcomes.
Company Contact Information
For further inquiries, please reach out to:
Snehal Patel
Investor Relations
Office: (832) 819-3232
Email: info@greenwichlifesciences.com
Frequently Asked Questions
What is the FLAMINGO-01 trial about?
FLAMINGO-01 is a Phase III clinical trial evaluating the immunotherapy GLSI-100 in preventing breast cancer recurrences in HER2 positive patients.
Why was Portugal added to the FLAMINGO-01 trial?
Portugal was added due to a significant incidence of breast cancer and the approval from European regulators to include more sites in the study.
Who is Dr. Luís António Marques da Costa?
Dr. Costa is the national principal investigator for FLAMINGO-01 in Portugal, with extensive expertise in oncology and clinical trials.
How many clinical sites are involved in the FLAMINGO-01 trial?
There are plans to activate up to 150 clinical sites globally for the FLAMINGO-01 trial.
What role does Greenwich LifeSciences play in cancer research?
Greenwich LifeSciences develops immunotherapies aimed at preventing breast cancer recurrences, focusing on innovative treatment strategies.
About The Author
Contact Lucas Young privately here. Or send an email with ATTN: Lucas Young as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
